Numerous experimental and clinical studies have established that the clinical outcome of chemotherapeutic strategies for breast cancer commonly rely on the expression of important growth factor receptors such as the nuclear estrogen receptors (ERs) [1]. This evidence concerns the gene ESR1 and breast carcinoma.